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Introduction
APR-246
APR-246 (APR) is a novel agent proposed to 
reactivate mutant p53 and consequential downstream 
biological effects, including induction of apoptosis.
The mechanism by which APR-246 reactivates p53 
and disrupts cellular redox along with sub sequential 
cytotoxic effects remain unknown.
https://https://www.frontiersin.org/articles/10.3389/fonc.2016.00021/full
Chronic Lymphocytic Leukemia (CLL) 
CLL is a B-cell malignancy most commonly treated with 
venetoclax or ibrutinib.
 Deletion of chromosome 17p and mutations of p53 
hallmark poor prognosis in patients with CLL.
5-8% of CLL patients incur dell17p, while p53 mutations 
exist in 10-15% of untreated CLL cases (40-50% in 
refractory disease). 
CLL patients with mutated p53 treated with frontline 
targeted therapies, venetoclax and ibrutinib, experience 
shorter progression-free survival.
Schematic of known APR-246 Mechanism
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Role of p53 in APR-246 Cytotoxicity
1. Determine role of p53 in the mechanism of APR-246-
induced cytotoxicity
2. Evaluate APR-246 alone and in combination with 
venetoclax and ibrutinib in isogenic cell line with different 
p53 background 
Does p53 status relate to APR-246 induced cytotoxicity?
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Conclusions
Does APR-246 treatment induce oxidative stress?






































































































































HG3-WT HG3-KO HG3-R175H HG3-R248Q
Treatment VTX VTX+APR VTX VTX+APR VTX VTX+APR VTX VTX+APR
IC50 3.46 3.24 3.42 1.989 3.695 3.403 3.697 3.376
R2 0.9753 0.9272 0.9578 0.8392 0.9169 0.8361 0.8941 0.871
Treatment IBR IBR+APR IBR IBR+APR IBR IBR+APR IBR IBR+APR
IC50 *** 6764 *** 7400 *** 14027 *** 14566
R2 0.8256 0.8431 0.8349 0.9032 0.8945 0.9013 0.7118 0.877
Does combining APR-246 with each venetoclax (VTX) and ibrutinib 



























p53/GSH Protein Immunoblot 
APR-246 is equally efficacious in cells with proficient, deficient, 
or mutated p53.
Mode of action of APR-246 is independent of p53 status, and 
glutathione depletion appears to be the primary mechanism.
APR-246 sensitizes CLL malignant B-cells to treatment with 
targeted therapies venetoclax and ibrutinib.
Why do these findings matter?
1. APR-246 may be useful in treating all CLL patients rather 
than solely p53-mutated.
2. APR-246 shows promise for treatment of other malignancies. 
3. A phase III clinical trial has been designed for patients with 
CLL to test APR-246 with ibrutinib or venetoclax.
Figure 2. HG3 cell line p53 protein expression 
was visualized via immunoblot. HG3WT had 
minimal expression of p53. HG3R175H and 
HG3R248Q both had increases in p53 expression 
when compared to WT. 
Figure 3. After both 24hrs and 48hrs of 
treatment with increasing doses of APR-246, 
there is no significant difference in cytotoxicity 
between HG3 cell lines and Mec1. Mec1 was not 
treated with APR75µM or APR100µM due its 
sensitivity to higher doses.
Figure 4. HG3 cell lines were treated with TBrT
and increasing doses of APR-246. APR50µM
produced the highest DCFDA fluorescence, 
indicating the highest levels of cellular ROS.
Figure 5. Mec1 cell line was treated with 
increasing doses of APR-246 and analyzed 
for DCFDA fluorescence. Treatment with 
APR20µM produced the highest levels of 
ROS in comparison to lower doses.
Figure 9. HG3 Cell lines were administered increasing doses of both ibrutinib alone and in 
combination with APR-246 for 72hrs and triplicated. In all four cell lines with varying p-53 status, 
ibrutinib combined with APR20µM induced significantly more cell death than ibrutinib as a single 
agent.
Figure 8. HG3 Cell lines were administered increasing doses of both alone and in combination with 
20µM APR-246 for 72hrs and triplicated. In all four cell lines with varying p-53 status, venetoclax 
combined with APR20µM induced significantly more cell death than venetoclax as a single agent. 
This effect was more pronounced at higher VTX doses.
Figure 6. Mec1 cells were treated with 50µM
of APR-246 for six hours. Relative 
illumination at 1 hour was 124, while 
illumination at 6 hours was 64, indicating 
that intracellular GSH concentration 
decreased by half. 
Figure 7. Mec1 cells were treated with APR10µM
and increasing amounts of glutathione. After 24-
hr incubation, cell viability was analyzed 
showing that Mec1 cells were rescued from cell 
death as dosage of GSH increased. 
Table 2. IC50 and R^2 Values for VTX, VTX+APR, IBR, and IBR+APR in HG3 cell lines
*** IC50values for IBR alone surpassed 20000nM, so could not be calculated
Figure 1. Schematic of Isogenic HG3 cell lines 
◼ Cell lines: CLL isogenic HG3 cell lines: wild-type (WT), 
knock-out (KO), two lines with hot-spot induced 
mutations: R175H and R248Q, and Mec1 cell line.
◼Cell viability quantified using FITC-Annexin/Propidium 
Iodide Flow Cytometry.
◼P53 and Glutathione (GSH)-associated protein 
expression  confirmed via Immunoblot.
◼Cellular ROS detected by DCFDA fluorescence through 
flow cytometry.
◼Intracellular GSH measured by Promega GSH-Glo 
Assay via luminometer. 
Materials and Methods
Role of APR-246 in Sensitization of Cells
Is there a cytotoxicity-related decline in glutathione after 
treatment with APR-246?
Time HG3-WT HG3-KO HG3-R175H HG3-R248Q Mec1
IC50
24hr 68.29 66.02 61.55 76.97 24.18
48hr 39.06 32.36 29.73 30.96 19.91
Table 1. IC50 values for HG3 and Mec1 cell lines after 24- and 48-hour treatment with APR-246
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HG3 Cell Lines (VTX/VTX+APR)






















































0 1 2 3 4
0
50
100
HG3-WT (n=3)
log dose (nM)
%
 C
e
ll
 V
ia
b
il
it
y
VTX
VTX+APR
